Tokai Pharmaceuticals to Participate in Upcoming Investment Conferences

RBC Capital Markets Global Healthcare Conference 2013

CAMBRIDGE, Mass.--()--Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that Martin D. Williams, president and chief executive officer, is scheduled to present at the 2013 RBC Capital Markets’ Healthcare Conference on Tuesday, February 26, 2013 at 9:00 a.m. (ET) in New York City. Mr. Williams will present an overview of the company and its lead prostate cancer candidate galeterone (TOK-001).

Tokai will also have a presence at the Citi 2013 Global Healthcare Conference taking place February 25-27, 2013 in New York City.

About Galeterone (TOK-001)

Galeterone is a proprietary small molecule, oral drug for the treatment of prostate cancer that disrupts androgen receptor signaling via a novel triple mechanism of action. In preclinical studies, galeterone acted as a highly selective CYP17 lyase inhibitor, as a potent androgen receptor antagonist, and decreased androgen receptor levels in prostate tumors – the only drug in development that has been shown to exhibit all three of these properties. Galeterone combines these three distinct mechanisms of action in one therapeutic compound. Results from the ARMOR1 Phase 1 clinical trial showed that galeterone demonstrated clinical activity and was well tolerated in patients with castration-resistant prostate cancer (CRPC). Galeterone is currently being evaluated in a Phase 2 study, ARMOR2, in patients with CRPC as part of the ARMOR (Androgen Receptor Modulation Optimized for Response) clinical development program.

About Tokai Pharmaceuticals

Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The company’s lead drug candidate, galeterone (TOK- 001), is the first investigational new drug that can decrease overall androgen receptor levels in prostate tumors and in which three distinct mechanisms of action are combined to disrupt androgen receptor signaling in one oncotherapeutic. Galeterone is currently being evaluated in a Phase 2 study, ARMOR2, in patients with castration-resistant prostate cancer (CRPC). Based in Cambridge, Massachusetts, Tokai is backed by Apple Tree Partners and Novartis Venture Fund. For more information on the company and galeterone, please visit www.tokaipharma.com.

Contacts

Pure Communications, Inc.
Caton Morris, 910-232-7166

Contacts

Pure Communications, Inc.
Caton Morris, 910-232-7166